4 February 2019 - - US-based medical technology company Senseonics Holdings, Inc. (NYSE-American: SENS) has extended its distribution agreement with Swiss health care group Roche's (SIX: RO) (OTCQX: RHHBY) Roche Diabetes Care business, the company said.

As extended, the agreement now runs through January 31, 2021.

Under terms of the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel.

In addition, the agreement has been expanded to provide Roche with exclusive distribution rights in 17 additional countries, including Brazil, Russia, India and China, as well as select markets in the Asia Pacific and Latin American regions.

Senseonics Holdings a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices.

The Eversense CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe.